Navigation Links
ARIUS announces fourth quarter and year-end fiscal 2007 financial results

TORONTO, Jan. 29 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the fourth quarter and fiscal year, ended November 30, 2007.

"Fiscal 2007 was a critical year in our development, highlighted by the significant advancement we made with the pre-IND programs for our lead drug candidates, our CD44 Cancer Stem Cell Program, our Trop-2 Signal Transduction Program, our CD59 Complement Inhibitor Program and our CD9 Cancer Stem Cell Program. The majority of our programs target cancer stem cells, an area that cancer researchers are particularly excited about as cancer stem cells have been implicated as the key cells responsible for the growth and spread of cancer," said Dr. David Young, President and CEO. "Building on this momentum, fiscal 2008 will be a pivotal year for us as we transition from a pre-clinical to a clinical company with the mission of moving one or more of our lead products into human clinical trials."

Program Updates:

CD44 Cancer Stem Cell Program

- Announced positive findings demonstrating no dose-limiting toxic

effects of ARIUS' lead therapeutic, ARH460-16-2, at doses up to

95 mg/kg in a dose-ranging pilot toxicology study in a non-human

primate model.

- Achieved significant and potent tumor growth inhibitory activity in

in vivo animal models of breast, prostate, liver, and AML cancers.

- Engaged the manufacturer Avid Bioservices to produce ARIUS' lead

anti-CD44 MAb under Current Good Manufacturing Practices ("cGMP") for

human clinical trials. Cell line producing the humanized anti-CD44

antibody was successfully transferred to Avid.

- Presented key data at AACR, ASCO, ASCO's Breast Cancer Symposium,


- Met with FDA to discuss plans

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, today ... partnering meetings taking place in the month of October: ... Partnering Forum RepliCel will be presenting at the ... on the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... Talon Innovations, a provider of ... other technology-driven industries, announces that it is one of three finalists for the Minnesota ... On Thursday, September 25 Talon Innovations was recognized as a nominee for this ...
(Date:10/7/2015)... , October 8, 2015 ... Medical biotechnology accounts for largest bioinformatics ... bioinformatics in drug discovery and development process ... . --> ... On the basis of applications, the bioinformatics ...
(Date:10/7/2015)... Worth, Texas (PRWEB) , ... October 07, 2015 ... ... Cell Institute ( ) will present a public educational seminar on the ... on Saturday, October 10th from 1:00 pm – 3:00 pm at the Hilton ...
Breaking Biology Technology:
... Private Life Science Companies from ... Southern California, ... life science community, is proud to announce that its,second annual BIOCOM ... from Oct. 31-Nov. 2, 2007. Featuring almost 60 innovative public ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... commercializing proprietary product candidates for the treatment,of ... Evan M. Levine,ADVENTRX,s chief executive officer, is ... Annual Growth Conference on Wednesday,September 19th, 2007 ...
... Agreement, COPENHAGEN, September 13 Genmab A/S ... exchange agreement with,Medarex, Inc. Under the terms of ... which targets IL-8, and Medarex will,receive full rights ... will release to each other all previously held ...
Cached Biology Technology:
(Date:10/6/2015)... LAKE CITY , Oct. 6, 2015 ... company, announced today that it has signed a contract ... monitoring services across the full range of sentences under ... Group,s President of the Americas. "This contract with the ... region of the US and advances our position as ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/30/2015)... Sept. 30, 2015  The U.S. Court of Appeals ... key ruling in favor of Crossmatch ™, affirming ... scanner company Suprema and its U.S. partner Mentalix violated ... trade provision that declares it unlawful to engage in ... two of Crossmatch,s patents, the 5,900,993 patent and the ...
Breaking Biology News(10 mins):
... successfully aiding in the replacement of narrowed, calcified ... open-chest surgery. According to a study reported at ... for Cardiovascular Angiography and Interventions (SCAI), May 9?2, ... with the CoreValve Revalving System (CoreValve, Irvine, CA) ...
... aimed at preventing cervical cancer is nearly 100 percent effective ... for most cases of cervical cancer. Results of a nationwide ... 9 issue of the New England Journal of Medicine. , ... deaths in women worldwide, resulting in nearly half a million ...
... at UNIVET, a spin-off of the Universitat Autònoma de ... Petcare, have developed an artificial cellular model which faithfully ... allow, therefore, the carrying out of various lines of ... need to use live animals. , The basic structure ...
Cached Biology News:
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
... Explorer processes up to 48 lanes, 24 ... input can be from either slab gel ... primer chemistries. The detection parameters in Explorer ... analyst consistency. We have built Explorer ...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Biology Products: